Compare HIHO & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIHO | CMND |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 2.2M |
| IPO Year | 2002 | 2021 |
| Metric | HIHO | CMND |
|---|---|---|
| Price | $0.85 | $0.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.3K | ★ 63.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 14.57% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.07 |
| 52 Week High | $2.21 | $3.25 |
| Indicator | HIHO | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 33.80 | 25.17 |
| Support Level | $0.77 | $0.08 |
| Resistance Level | $1.04 | $1.07 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 4.21 | 4.70 |
Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.